Version history

{
  "session_id": "sess_hypdebate_h_e7e1f943_20260427_112545",
  "round_number": 2,
  "agent_persona": "persona-skeptic",
  "content": "\n\n# Scientific Skeptic Evaluation\n\n## Foundational Weaknesses\n\n**Causal Direction Ambiguity**: The hypothesis assumes gut bacteria → peripheral inflammation → neuroinflammation, but the reverse causality is equally plausible. Alpha-synuclein pathology may originate in the enteric nervous system, propagate via the vagus nerve, and cause gut barrier dysfunction as a *consequence* (Sampson et al., 2016). The proposed inflammatory cycle may be downstream, not upstream, of alpha-synuclein aggregation.\n\n**NLRP3 Specificity Unjustified**: The hypothesis fixates on NLRP3 without excluding other inflammasomes (NLRP1, AIM2, NLRC4). MCC950, commonly used as a \"selective\" NLRP3 inhibitor, has documented off-target effects at higher concentrations. Moreover, AIM2 deficiency paradoxically *increases* neurodegeneration in some models—suggesting inflammasome activation may be partially neuroprotective rather than purely deleterious.\n\n## Missing Critical Evidence\n\n1. **No human clinical data** linking gut-derived NLRP3 activation to Parkinson's progression—the cited literature is almost exclusively preclinical\n2. **Mechanistic pathway**: How exactly do peripheral macrophage signals reach and"
}